[Summary] Research and development of stem cell drugs
1. Industry Background:
With the rapid development of cell and gene drugs, humanity will enter the era of cell and gene therapy in the 21st century! The Ministry of Science and Technology's key science and technology program "Stem Cell Research and Organ Repair" has funded stem cell therapy research for consecutive years, and multiple departments including the National Health Commission and the National Medical Products Administration have issued documents requiring acceleration of the clinical application of stem cells and regenerative medicine!
Currently, multiple CAR-T therapeutic products have been approved for marketing in China. Our company is mainly engaged in the development of universal stem cell therapeutic drugs, focusing on drug development for immune diseases and refractory diseases, and has obtained multiple registration clinical and IIT clinical approvals.
2. Scale:
The company has completed Phase I construction of a 4,200-square-meter workshop and R&D site, with a total investment exceeding 50 million yuan. It is designed according to the EU's GMP fATMP standards dedicated to cell production, and is equipped with over 300 sets of large instruments and equipment including flow cytometers, QPCR, and cell factory observation stations; the B+A grade real-time microbial monitoring system, isolator preparation technology, one-way personnel and material flow management system, and strict full-process aseptic operation specifications have enabled the preparation and quality control of pharmaceutical-grade cell products!
The company has initiated the planning and construction of Phase II project located in Jiangning High-tech Zone, which will build a headquarters R&D and production base for "advanced therapy medicinal products" represented by cell, nucleic acid, and gene drugs, striving to create a center for cutting-edge drug R&D and translational application in China.
3. Talent Team and Projects:
The company fully practices the principles of R&D-driven and drug development for the people. Academician Wang Guangji of the Chinese Academy of Engineering serves as the company's legal representative and chairman, and multiple professors and scholars have been hired as advisors for pharmaceutical and clinical research, focusing on the druggability research of cell products and the industrial transformation of cell products for treating difficult and severe diseases.
More than 65% of the company's current scientific research team holds master's or doctoral degrees, and the company values employees' continuing education and skill improvement, supporting employees to pursue master's and doctoral studies while employed. As of September 2022, the company has applied for 17 intellectual property rights, with 5 authorized, 3 innovative cell drugs in research, and 2 clinical trials underway, with indications covering major diseases such as active lupus nephritis, refractory lupus nephritis, multiple sclerosis, and diabetic nephropathy (the company obtained registration clinical trial approval in only 2.5 years based on clinical efficacy-based reverse derivation of druggability development).
4. Qualifications:
The company has a New Drug Research Center, GMP Preparation Center, and Clinical Medicine Center, committed to building an international-standard cell product transformation platform, and building cell preparation workshops in accordance with domestic GMP requirements and EU GMP standards.
The company has established clinical research relationships with medical institutions such as Nanjing Drum Tower Hospital, Jiangsu Province Hospital, Subei People's Hospital, and the Affiliated Hospital of Xuzhou Medical University, and has established scientific research cooperation relationships with research institutes such as Nanjing University, China Pharmaceutical University, Nanjing Medical University, and Jiangsu Institute of Nuclear Medicine, and is leading and participating in multiple science and technology programs.
The company has been awarded honors and qualifications such as "Technology-based SME," "Nanjing 2022 Cultivated Unicorn," and "Jiangning High-tech Zone 2021 Three-Star Party Organization," and is a party building contact point for high-level talents in Jiangning District.
What does Jiangsu Ruiyuan Biotechnology Co., Ltd. require? Who is Ruiyuan Biotech hiring? Ruiyuan Biotech recruitment: Biology/Pharmaceutical/Chemical/Environmental Protection占比最多占50%,其次是Business Management占42.3%. What education can get in at Ruiyuan Biotech? 本科占比最多占53.8%,其次是硕士占30.8%. High education required at Ruiyuan Biotech? 硕士占30.8%. Work experience required at Ruiyuan Biotech? 不限占比最多占46.2%,其次是3-5年占30.8%. Where are the job locations at Ruiyuan Biotech? 南京占比最多占100%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows